Imatinib-induced apoptosis: A possible link to topoisomerase enzyme inhibition by Baran, Yusuf et al.
ORIGINAL ARTICLE
Imatinib-induced apoptosis: a possible link to
topoisomerase enzyme inhibition
Y. Baran* PhD, S. Zencir MSc, Z. Cakir* BSc, E. Ozturk BSc and Z. Topcu§ PhD
*Department of Molecular Biology and Genetics, Faculty of Sciences, Izmir Institute of Technology, Izmir,
Department of Biochemistry, Faculty of Sciences, Ege University, Izmir, Department of Biology, Faculty
of Sciences, Ege University, Izmir, and §Department of Pharmaceutical Biotechnology, Faculty of
Pharmacy, Ege University, Izmir, Turkey
SUMMARY
What is known and Objective: Imatinib is a spe-
cific BCR ⁄ABL inhibitor, commonly used for the
treatment of chronic myeloid leukaemia (CML), a
hematological malignancy resulting from a chro-
mosomal translocation that generates the
BCR ⁄ABL fusion protein. Recent studies showed
that the imatinib has cytotoxic and apoptotic
effects on many BCR ⁄ABL-negative cancers.
Numerous compounds with cytotoxic potential
exert their functions by interfering with the DNA
topoisomerase. In this study, we examined the
effects of imatinib on tumour cell-killing in
relation to DNA topoisomerase enzyme inhibi-
tion.
Methods: We determined the cytotoxicity by cell
proliferation assay (XTT; tetrazolium hydroxide),
using the human K562 CML cells, and loss of
mitochondrial membrane potential by monitor-
ing the changes in caspase-3 enzyme activity.
Type I and II topoisomerase activities were
measured by supercoiled plasmid relaxation and
minicircle DNA decatenation assays respec-
tively.
Results and Discussion: Imatinib-induced apop-
tosis and inhibited cell proliferation in a dose-
dependent manner. We also found that the
imatinib was effective in both type I and type II
topoisomerase reactions to a varying degree
between 94% and 7% for the concentration range
of 1 mM–0Æ02 mM in a dose-dependent manner.
What is new and Conclusion: Our results suggest
that the inhibition of topoisomerases may be a
significant factor in imatinib-induced apoptosis
in CML.
Keywords: apoptosis, BCR ⁄ABL, chronic myeloid
leukaemia, imatinib, topoisomerase
WHAT IS KNOWN AND OBJECTIVE
Chronic myeloid leukaemia (CML) is a hemato-
poietic stem cell disorder, characterized by an
increased number of immature white blood cells (1,
2). CML is diagnosed by the presence of BCR ⁄ABL
oncogene, resulting from a reciprocal translocation
between the long arms of chromosomes 9 and 22,
and formation of the diagnostic Philadelphia
chromosome (Ph). The BCR ⁄ ABL hybrid gene
encodes a fusion protein with constitutive tyrosine
kinase activity that induces leukaemogenesis (3).
Imatinib is the first target-specific anticancer agent
for the treatment of cancers including Ph-positive
CML and gastrointestinal stromal tumours (4). It
specifically recognizes and binds to the ATP bind-
ing site of BCR ⁄ABL and inhibits its activity (5).
Inhibition of BCR ⁄ ABL activity modulates the
expression of several genes involved in the regu-
lation of cell growth, proliferation, apoptosis, cell
cycle, cell adhesion and differentiation (6).
Platelet-derived growth factor receptors
(PDGFR), colony stimulating factor 1 receptor
(CSF1R) and c-KIT are also the targets of imatinib.
These molecules are highly expressed in many
BCR ⁄ABL-negative cancer types such as dermato-
fibrosarcoma protuberans (DFSP), melanoma,
chordoma and aggressive fibromatosis, and gastro-
intestinal stromal tumours (GIST). In GIST, imatinib
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blocks the activity of mutant or wild-type c-KIT
tyrosine kinase (7, 8). We have previously reported
that imatinib induces apoptosis by increasing the
intracellular concentrations of apoptotic ceramides
via generation and accumulation of ceramides by
upregulating ceramide synthase genes and down-
regulating the anti-apoptotic sphingosine kinase-1
gene (9). We have evidence indicating that imatinib
induces autophagy and programmed cell death-II,
by increasing the expression levels of Atg5, Atg6 and
LC-3 genes in a dose-dependent manner (unpub-
lished data). However, the mechanisms of imatinib-
induced apoptosis in BCR ⁄ABL-negative cancers
are yet to be clarified.
Numerous naturally occurring and synthetic
compounds with cytotoxic and anticancer proper-
ties interfere with the normal DNA topoisomerase
functions (10–16) and DNA-protein interactions
(17). Topoisomerases are essential enzymes playing
important roles in many genetic processes,
including the DNA replication, transcription,
recombination and transposition (18). There are
two types of topoisomerases; Type I topoisome-
rases (topo I) make a single-stranded break in a
DNA duplex, mediate passage of the intact strand
through the break, and then reseal it. Type II
topoisomerases, on the other hand, create transient
breaks in both the strands of a duplex, pass an
intact DNA segment through the break and then
reseal the cleavage site (19, 20). All known type II
topoisomerases require ATP for their catalytic
activities in topoisomerization reactions.
In this study, we have determined the cytotox-
icity and loss of mitochondrial membrane potential
using imatinib. As topoisomerases have been rec-
ognized as an effective target for the development
of chemotherapeutics, we extended our research to
cover the mammalian DNA topoisomerase assays
for assessing the biological activities of imatinib.
METHODS
Cell culture
Human K562 CML cells were obtained from Ger-
man Collection of Microorganisms and Cell Cul-
tures and maintained in RPMI1640 medium
containing 10% foetal bovine serum and 1% strep-
tomycin–penicillin at 5% CO2 incubator at 37 C
(NuAire Laboratory Equipment Supply, MN, USA).
XTT Cell proliferation assay
Cell proliferations were determined by XTT cell
proliferation assay (Biological Industries, Kibbutz
Beit Haemek, Israel) as described (21). 2 · 104 cells
were grown in a 96-well plates containing 200 lL
growth medium per well in the absence or pres-
ence of increasing concentrations of imatinib and
incubated at 37 C in 5% CO2 incubator. Following
72 h incubation, 50 lL XTT reagent was added to
each well and then incubated for another 4 h.
Finally, the absorbance was measured by ELISA
reader under 490 nm wavelength of light (Thermo
Electron Corporation Multiskan Spectrum, Vantaa,
Finland).
Detection of apoptosis by caspase-3 enzyme
activity and mitochondrial membrane potential
(MMP)
Changes in caspase-3 enzyme activity in response
to imatinib were measured by caspase-3 colori-
metric assay as described (R&D Systems, Minne-
apolis, USA) (21). Briefly, the K562 cells were
treated with different concentrations of imatinib
and incubated for 72 h. The cells were collected by
centrifugation at 800 g for 10 min. The pellets were
lysed on ice for 10 min, centrifuged at 10 000 g for
1 min and supernatants were transferred into a new
tube. To determine caspase-3 enzyme activity,
50 lL of reaction buffer (5X), 5 lL of caspase-3
colorimetric substrate, and 50 lL of the samples
were applied to the cell suspensions in 96-well plate
and incubated for 2 h at 37 C in 5% CO2 incubator.
Absorbance of the samples was read under 405 nm
wavelength of light via the ELISA (Thermo Electron
Corporation Multiskan Spectrum, Vantaa, Finland).
Protein concentrations were determined by Brad-
ford assay and caspase-3 enzyme activity levels
were normalized to protein concentrations.
Loss of mitochondrial membrane potential (MMP)
The mitochondrial membrane potential was
detected by JC-1 MMP kit as described by the
manufacturer (Cell Technology, CA, USA). K562
cells were treated with imatinib as described above.
The pellets were collected by centrifugation at
800 g for 10 min and then treated with 500 lL of
JC-1 dye before their incubation at 37 C in 5% CO2
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for 15 min. These mixtures were centrifuged at
800 g for 5 min, and then mixed with the 2 mL of
blank media. After centrifugation at 800 g for
5 min, the pellets were dissolved in 500 lL of blank
media and 150 lL from each sample was trans-
ferred into 96-well plates. The aggregate red form
of the dye which is found in inner mitochondria
has absorption ⁄ emission maxima of 585 ⁄ 590 nm,
and the monomeric green form of the dye which
was released to the cytoplasm due the loss of the
MMP has absorption ⁄ emission maxima of 510 ⁄
527 nm. The plate was read at these wavelengths
by fluorescence Elisa reader ELISA (Thermo
Electron Corporation Multiskan Spectrum, Vantaa,
Finland). Finally, green ⁄ red (510 ⁄ 585) values were
calculated to determine the changes in MMP.
Topoisomerase I supercoiled plasmid relaxation
assay
Supercoiled plasmid relaxation assays were carried
out as previously described (14, 22). Briefly, 20 lL
of reaction mixture contained 500 ng of superheli-
cal circular (sc) plasmid DNA, one unit of calf
thymus topo I (TAKARA, Otsu-Shiga, Japan) in the
presence or absence of the Imatinib in the reaction
buffer (35 mM Tris–HCl (pH 8Æ0), 72 mM KCl, 5 mM
MgCl2, 5 mM DTT, 5 mM spermidine and 0Æ1%
bovine serum albumin). Relaxation products were
separated on 1% agarose gels in TBE buffer (45 mM
Tris–Borate and 1 mM EDTA, pH 8Æ0) in a hori-
zontal electrophoresis apparatus (5 V ⁄ cm) (Thermo
EC250, Waltham, MA, USA). Electrophoresis was
continued until the bromophenol blue dye had
migrated 75% down the gel and photographed
under UV light after staining in ethidium bromide
(Etd-Br) solution (0Æ5 lg ⁄mL). The relationship
between the binding of Etd-Br and the amount of
fluorescence given by sc and relaxed DNA (rlx
DNA) under UV light was carried out as described
(23, 24). DNA bands were quantified from gel
photo images using BioRad Multianalyst (ver. 1Æ1).
Average band intensities were calculated from
three independent reactions.
Topoisomerase II decatenation assays
Decatenation assays were carried out using 0Æ2 lg
kinetoplast DNA (K-DNA) substrate in a final
volume of 20 lL in topo II reaction buffer (50 mM
Tris–Cl, pH 8Æ0, 120 mM KCl, 10 mM MgCl2. 0Æ5 mM
ATP, 0Æ5 mM dithiothreitol) (25). Reactions were
terminated with stop buffer (5% sarkosyl, 0Æ0025%
bromophenol blue, 25% glycerol) and electropho-
retic analyses of K-DNA were performed using
standard agarose gel containing 0Æ5 lg Etd-Br ⁄mL.
Resolution of decatenated DNA products were
monitored as stated above except the gels were
destained in water prior to the photography. Eto-
poside, a well-known topoisomerase II inhibitor
was used as a control.
RESULTS AND DISCUSSION
Imatinib inhibits proliferation of K562 cells in a
dose-dependent manner
We examined the proliferation rates of K562 cells in
response to increasing concentrations of imatinib
for 72 h by XTT assay. The results revealed that
there were 9%, 14%, 22%, 27%, 35% and 87%
decreases in cell proliferation in response to 0Æ5, 5,
50, 100, 200 and 600 nM imatinib respectively, as
compared with untreated controls. We could not
detect any significant change in the proliferation of
K562 cells in response to 0Æ1 nM imatinib as com-
pared with the untreated controls whereas 600 nM
imatinib showed the highest anti-proliferative
effect (Fig. 1). IC50 (drug concentrations that
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Fig. 1. Effects of imatinib on the growth of K562 cells.
The IC50 concentration of imatinib was calculated from
cell proliferation plots. The XTT assays were performed
using triplicate samples in at least two independent
experiments. The error bars represent the SD, and when
not seen, they are smaller than the thickness of the lines
on the graphs. Statistical significance was determined
using ANOVA, and (P < 0Æ05) was considered significant.
[Correction made on 12 October 2011, figure 1 has been
replaced with the corrected figure.]
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inhibits 50% of cell proliferation) value of imatinib,
calculated from cell proliferation plots was 310 nM
(Fig. 1). [Corrections added on 12 October 2011,
after online publication: The sentence ‘The results
revealed that there were 6%, 12%, 16%, 26%, 80%
and 84% decreases in cell proliferation in response
to 0.1, 1, 10, 100, 500 and 1000 nM imatinib
respectively, as compared with untreated controls
(Fig. 1)’ was corrected to ‘The results revealed that
there were 9%, 14%, 22%, 27%, 35% and 87%
decreases in cell proliferation in response to 0.5, 5,
50, 100, 200 and 600 nM imatinib respectively, as
compared with untreated controls’, ‘500 nM imati-
nib’ was corrected to ‘600 nM imatinib’ and 280 nM
was corrected to 310 nM.]
Imatinib induces apoptosis in a dose-dependent
manner
To examine the apoptotic effects of imatinib on
K562 cells, we incubated the cells with four dif-
ferent concentrations of imatinib and examined the
changes in caspase-3 enzyme activity and loss of
mitochondrial membrane potential. We choose
IC50 and lower concentrations of imatinib (50, 150,
250 and 300 nM) to assess the strength of apoptotic
effects of imatinib. The results revealed that incu-
bation of K562 cells in the presence of 50, 150, 250
and 300 nM imatinib resulted in 13%, 37%, 40%
and 54% increases in caspase-3 enzyme activity
compared with the untreated control group
(Fig. 2), To confirm these results, we examined the
changes in MMP and observed that the same doses
of imatinib caused 14%, 28%, 46% and 51%
increases in cytoplasmic ⁄monomeric JC-1 relative
to the untreated control cells (Fig. 3). The observed
differences seen with both caspase-3 enzyme
activity and mitochondrial membrane potential
were statistically significant (P > 0Æ05). [Corrections
added on 12 October 2011, after online publication:
‘incubated the cells with two different concentra-
tions of imatinib’ was corrected to ‘incubated the
cells with four different concentrations of imatinib’,
the sentence ‘We choose IC50 dose, 280 nM and
10 nM to assess the strength of apoptotic effects of
imatinib’ was corrected to ‘We choose IC50 and
lower concentrations of imatinib (50, 150, 250 and
300 nM) to assess the strength of apoptotic effects of
imatinib’, the sentence ‘The results revealed that
incubation of K562 cells in the presence of 10 and
280 nM imatinib resulted in 27% and 58% increases
in caspase-3 enzyme activity compared with the
untreated control group (Fig. 2) was corrected to
‘The results revealed that incubation of K562 cells
in the presence of 50, 150, 250 and 300 nM imatinib
resulted in 13%, 37%, 40% and 54% increases in
caspase-3 enzyme activity compared with the
untreated control group (Fig. 2) and ‘31% and 50%
increases’ was corrected to ‘14%, 28%, 46% and
51% increases’]
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Fig. 2. Percent changes in caspase-3 enzyme activity in
imatinib exposed K562 cells. The results are the means of
two independent experiments. The error bars represent
the SD. Statistical significance was determined using
ANOVA, and (P < 0Æ05) was considered significant. [Cor-
rection made on 19 January 2011, figure 2 has been
replaced with the corrected figure.]
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Fig. 3. Percent changes in cytoplasmic ⁄ monomeric JC-1
in imatinib treated K562 cells. The results are the means
of two independent experiments. The error bars repre-
sent the SD. Statistical significance was determined using
ANOVA, and (P < 0Æ05) was considered significant. [Cor-
rection made on 12 October 2011, figure 3 has been
replaced with the corrected figure.]
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Imatinib interferes with both type I and type II
topoisomerase reactions
We carried out plasmid DNA nicking and DNA
decatenation assays to monitor the effect of imati-
nib on topoisomerase I and topoisomerase II
reactions respectively. Topoisomerase I assay
employs supercoiled plasmid DNA (sc DNA) and
relies on the ability of the enzyme to convert sc
DNA to its relaxed form, which can be separated as
discrete bands using gel electrophoresis. An inhi-
bition of relaxation activity due to the presence of a
particular inhibitor was monitored in the form of
an accumulated faster-migrating sc DNA. On the
other hand, topoisomerase II assay was based on
the decatenation of K-DNA, minicircles from the
insect trypanosome Crithidia fasciculata (25). As
K-DNA is an aggregate of interlocked DNA mini-
circles, resulting high molecular weight would
prevent the substrate population from entering the
gel, unless the K-DNA is decatenated by the
enzyme, topoisomerase II. Inclusion of Etd-Br in
the gel enabled us to monitor open-circular
monomers and covalently closed circular DNA
bands.
A representative assay using various concentra-
tions of imatinib is given in Fig. 4. As seen in
Fig. 4A, sc plasmid substrate, pBR322 (Fig. 4A, lane
1) is relaxed by topo I (Fig. 4A, lane 2) in the
absence of imatinib. However, the reaction was
profoundly affected by 1 mM imatinib (Fig. 4A,
lane 3). The interference by imatinib gradually
decreased upon the dilution to imatinib to 0Æ5 mM
and 0Æ1 mM (Fig. 4A, lanes 4 and 5 respectively).
This effect completely disappeared when the con-
centration of imatinib was lowered to 0Æ02 mM
(Fig. 4A, lane 6). At this level, only a very faint sc
DNA band with an accumulated lower migrating
relaxed DNA (rlx DNA) was seen. Densitometric
calculations of relative band intensities showed
that the interference was 94% at 1 mM imatinib
concentration and this value gradually decreased
(a) (b)
Fig. 4. The effect of imatinib on mammalian DNA topoisomerase I activity. (a) A representative agarose gel photograph
of supercoil relaxation in the presence of varying concentrations of imatinib; lane 1, pBR322; lane 2, pBR322 with 1 U of
DNA topoisomerase I; lanes 3–6, same as lane 2 plus 1 mM, 0Æ5 mM, 0Æ1 mM and 0Æ02 mM Imatinib respectively. (b)
Quantitative assessment of the reaction profile corresponding to samples from lanes 3 to 6 (see ‘Materials and methods’
for the details).
Fig. 5. Decatenation assays by topoisomerase II in the
presence or absence of imatinib. Lane 1, K-DNA; lane 2,
K-DNA with 1 U of DNA topoisomerase II; lane 3, same
as lane 2 plus 0.5 mM etoposide; lane 4, same as lane 2
plus 1 mM Imatinib; lane 5, linear DNA marker; lane 6,
decatenated DNA marker.
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to 18%, 14% and 7% upon serial dilutions
(Fig. 4B). Residual nicked circular DNA present in
the plasmid preparation was taken into account in
the quantitative evaluations. We next employed the
decatenation assays by topoisomerase II in the
presence or absence of imatinib (Fig. 5). As seen in
Fig. 5, the K-DNA was too large to enter the gel
(Fig. 5, lane 1) whereas topoisomerase II yielded
monomeric DNA rings of two species, OC-DNA
and CCC-DNA (Fig. 5, lane 2). The reaction was
completely abolished in the presence of etoposide
(Fig. 5, lane 3). Likewise, 1 mM imatinib interfered
with the decatenating activity of topoisomerase II
(Fig. 5, lane 4) leaving catenated DNA molecules.
The last two lanes indicate the linear (Fig. 5, lane 5)
and catenated DNA (Fig. 5, lane, 6) markers.
Our results revealed that imatinib-induced
apoptosis and inhibited cell proliferation in a dose-
dependent manner. Moreover, we also showed that
the imatinib inhibited topoisomerase I and II
enzymes activities in a dose-dependent manner,
in vitro. The pharmacological significance of topoi-
somerases in anti-cancer drug development is well-
known (10–16). However, the compounds targeting
these enzymes are structurally different, which
suggests that there is not a unique mechanism for
topoisomerase inhibition. Several studies in mam-
malian cells, employing cytotoxic agents with topo-
isomerase-targeting properties, suggest that the
cellular responses were related to the formation of a
drug ⁄ enzyme ⁄DNA cleavable complex. Such a
cleavable complex is formed, not through the inhi-
bition of the catalytic activity of topoisomerases but
through a mechanism involving the DNA damage
(19). All known topoisomerase-targeting drugs,
specifically and reversibly block the DNA rejoining,
and results in the trapping of a covalent enzyme ⁄
DNA intermediate (26, 27). The reversibility of the
damage is a main difference between the actions of
imatinib on topoisomerase reactions and apoptosis.
Although our results showed that the imatinib pro-
motes apoptosis through increasing caspase-3
enzyme activity and loss of mitochondrial mem-
brane potential as well as interfering with the topo-
isomerase activities as shown in Figs 4 and 5, the
concentrations used in two assays were different. As
in the former test, an irreversible-damage is asses-
sed, the concentrations of imatinib, expected to
inhibit topoisomerase reactions and apoptosis,
would not be expected to be the same.
WHAT IS NEW AND CONCLUSION
Unlike type I enzymes, identification of topoisom-
erase II-targeting chemicals is relatively recent. Our
results demonstrate that imatinib blocked the
decatenation activity of topo II, thereby suggesting
a possible mechanism for imatinib-induced tumour
cell-killing.
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